Kintara Therapeutics Inc., a biopharmaceutical company investigating REM-001 in an NIH-sponsored and funded open label study in cutaneous metastatic breast cancer, and TuHURA Biosciences, Inc., a Phase 3 registration-stage immune-oncology company developing novel technologies to overcome resistance to cancer immunotherapy, have entered into a definitive agreement for an all-stock transaction forming a company with expertise and resources to advance a risk diversified late-stage oncology pipeline...